nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program

Mark A Dickson, MD¹; Vinod Ravi, MD²; Richard F Riedel, MD³; Kristen N Ganjoo, MD⁴; Brian A Van Tine, MD, PhD⁵; Rashmi Chugh, MD⁶; Lee D Cranmer, MD, PhD⁷; Erlinda Maria Gordon, MD⁸; James L Chen, MD⁹; Martina C Murphy, MD¹⁰; Anita N Schmid, PhD¹¹; Neil Desai, PhD¹¹; Norma Alonzo Palma, PhD¹¹; David J Kwiatkowski, MD, PhD¹²; Andrew J Wagner, MD, PhD¹³

¹Memorial Sloan Kettering Cancer Center, New York, NY; ²The University of Texas MD Anderson Cancer Center, Houston, TX; ³Duke Cancer Institute, Duke University Medical Center, Santa Monica, CA; ⁹The Ohio State University, Columbus, OH; ¹⁰University of Florida, Gainesville, FL; ¹¹Aadi Bioscience, Pacific Palisades, CA; ¹²Brigham and Women's Hospital, Boston, MA; ¹³Dana-Farber Cancer Institute, Boston, MA; ¹³Dana-Farber Cancer Institute, Boston, MA

INTRODUCTION

- Inactivating alterations in TSC1 or TSC2 are considered targetable biomarkers for mTOR inhibition¹
- nab-Sirolimus is an albumin-bound mTOR inhibitor (mTORi) approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa, a tumor that frequently has inactivating alterations in TSC2 or TSC1^{2,3}
- The AMPECT trial (NCT02494570) of nab-sirolimus efficacy and safety was the first prospective study in advanced malignant PEComa⁴
- In exploratory biomarker analyses, known inactivating alterations in TSC1 or TSC2 were associated with response
- To allow access to *nab*-sirolimus treatment for patients with serious conditions who were excluded from AMPECT, an expanded access program (EAP; NCT03817515) bridged the gap between closure of enrollment in the AMPECT trial and *nab*-sirolimus market access
- We report data from the final analysis of AMPECT patients, who were naïve to mTORi, and from patients with malignant PEComa with prior mTORi exposure treated with *nab*-sirolimus in the EAP

SAFETY

- There were no Grade 4 or 5 treatment-related AEs (TRAEs) in AMPECT
- The most common TRAEs in AMPECT were mucositis, fatigue, and rash (**Table 1**) • Four patients with a response had TRAEs that were managed with dose reduction; these patients maintained response on the lower dose
- AEs reported by the treating physician in the EAP were consistent with what was reported in AMPECT

Table 1. Most frequent TRAEs and Grade 3 TRAEs in AMPECT

TRAEs	Any grade (>25%)	Grade 3
Hematologic TRAEs		
Anemia	18 (53)	5 (15)
Thrombocytopenia	12 (35)	1 (3)
Nonhematologic TRAEs		
Mucositis	27 (79)	6 (18)
Fatigue	21 (62)	1 (3)
Rash	21 (62)	
Nausea	16 (47)	
Diarrhea	14 (41)	
Hyperglycemia	14 (41)	3 (9)
Weight decreased	14 (41)	
Dermatitis	12 (35)	
Hypertriglyceridemia	11 (32)	1 (3)
Hypercholesterolemia	11 (32)	
Decreased appetite	12 (33)	
Dysgeusia	9 (26)	
Headache	10 (29)	
ALT	9 (26)	1 (3)
Edema	9 (26)	
Pruritus	9 (26)	
Vomiting	9 (26)	1 (3)

AMPECT


- Age ≥18 years


- ECOG PS 0-1

Tar tio Õ Į



ALT. alanine aminotransferase: TRAE. treatment-related adverse event





CONCLUSIONS

nab-Sirolimus provided clinical benefit in mTORi-naïve patients with malignant PEComa in the AMPECT trial and in patients with malignant PEComa with prior mTORi therapy in an EAP Although AMPECT and the EAP cannot be directly compared, response rates showed similar trends regardless of prior mTORi exposure and in patients with TSC1 or TSC2 alterations Based on the emerging biomarker results, a tissue-agnostic pan-tumor Phase 2 study in patients with TSC1 and TSC2 alterations has been initiated and is currently enrolling patients (NCT05103358)

AMPECT

- 31 patients with malignant PEComa and no prior mTORi exposure are shown as of June 2021
- ORR was 39% (12/31 patients), including 2 CRs, and DCR was 71%
 - Median DOR was not reached after 3 years of follow-up, indicating that >50% of patients will have a DOR >36 months
 - No clinically relevant differences by baseline characteristics were noted
 - Patients obtained benefit regardless of TSC1 and TSC2 alteration status
 - During long-term follow-up, 2 patients ineligible for tumor resection at
 - baseline had successful resection after treatment with *nab*-sirolimus

Table 2. Best overall response in all evaluable patients and patients with known inactivating alterations in *TSC1* or *TSC2* in AMPECT

	Patients	CR or PR ^a	SD	PD
All evaluable patients	31	12/31 (39%)	16/31 (52%)	3/31 (10%)
TSC1 or TSC2 alteration	14	9/14 (64%)	5/14 (36%)	0

4/31 patients, all with response, were ongoing at the data cutoff CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease

FAP

- 16 patients with malignant PEComa and prior mTORi exposure were treated on the EAP from July 2019–July 2021; prior mTORi included sirolimus, everolimus, temsirolimus, and sapanisertib; 12 patients had exposure to 1 prior mTORi and 4 patients had exposure to ≥2 prior mTORis; and 50% had had progressive disease as best response on previous mTORi
- The DCR was 63% (10/16)

Table 3. Best overall response in all evaluable patients and patients with known inactivating alterations in *TSC1* or *TSC2* on the EAP

Patients	PR ^a	SD	PD
16	4/16 (25%)	8/16 (50%) ^b	4/16 (25%)
9	4/9 (44%)	3/9 (33%)	2/9 (22%)
	16	16 4/16 (25%)	16 4/16 (25%) 8/16 (50%) ^b

/16 patients including 2 without alterations in *TSC1* or *TSC2* were ongoing at the time of data cutoff Confirmed responses. ^b6/16 patients had SD for ≥12 weeks. EAP, expanded access program; PD, progressive disease; PR, partial response; SD, stable disease

REFERENCES

. Huang J, et al. *Biochem J.* 2008 ; 412(2) :179–90. FYARRO (sirolimus albumin-bound particles for injectable suspension). Package insert. Pacific Palisades, CA. Aadi Bioscience, Inc.; 2021. Martignoni G, et al. Virchows Arch. 2008;452:119–132.

4. Wagner AJ, et al. J Clin Oncol. 2021;39(33):3660–70.

ACKNOWLEDGMENT This study was funded by Aadi Bioscience, Inc. Editorial support was provided by Hilary Durbano, PhD, of AlphaBioCom, LLC, King of Prussia, PA, USA, and funded by Aadi Bioscience, Inc.